Zelgen Biopharmaceuticals' drug included in national medical insurance catalog

Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that its self-developed Gicacasitine Hydrochloride Tablets (trade name: Zeppuping) have been successfully included in the 2025 National Medical Insurance Drug Catalog. This inclusion, which follows a national medical insurance negotiation, will take effect on January 1, 2026, and is valid until December 31, 2027.

Gicacasitine Hydrochloride Tablets are a Class 1 new drug and a novel JAK inhibitor, approved for the treatment of intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) in adult patients. The drug is classified as a Class B nationally negotiated medicine.

The company anticipates that this inclusion will positively impact product sales and enhance the drug's affordability and accessibility for patients. While beneficial for the company's long-term operational development, no significant impact on short-term operating performance is expected. Investors are advised to exercise caution and be aware of investment risks.